Results 31 to 40 of about 21,276,636 (264)
The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer [PDF]
, 2010 <b>Background & aims:</b> The involvement of a systemic inflammatory response, as evidenced by the Glasgow Prognostic Score (GPS), is associated with weight loss and poor outcome in patients with non-small cell lung cancer.
Meek, C.L. +3 more
core +1 more source
Regulation of Mitochondria-dependent Apoptosis in Non-Small Cell Lung Cancer: Implications for Cancer Therapy [PDF]
, 2007 Summary The work described in this thesis focuses on the characterization of the mechanism(s) underlying the deregulated activation of the intrinsic or mitochondrial apoptotic pathway in non-small cell lung cancer (NSCLC) cells.
Checinska, A.
core
Pediatric Blood &Cancer, EarlyView.ABSTRACT As part of the European Cooperative Study Group for Paediatric Rare Tumours initiative, we developed standard clinical practice guidelines for ovarian sex cord stromal tumors, based on comprehensive national and international cohort analyses, literature review, and a final expert consensus conference.
Dominik T. Schneider +15 more
wiley +1 more source
Quality of life in patients receiving platinum based chemotherapy for advanced non-small cell lung cancer. [PDF]
, 2006 Quality of life in patients receiving platinum based chemotherapy for advanced non-small cell lung cancer. Lung cancer is the cause of 34,000 deaths in the UK each year, with a five year survival rate of only 7.5%.
Leary, A.
core
Development of taxane resistance in a panel of human lung cancer cell lines [PDF]
, 2008 Using a selection process designed to reflect clinically relevant conditions, a panel of taxane-selected variants were developed to study further the mechanisms of resistance in lung cancer.
Keenan, Joanne +3 more
core +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Rates of cancer among adolescents and young adults (AYA), age 15–39 years, are increasing. Consequently, radiation oncologists are treating more AYAs who have diagnoses spanning both pediatric and adult practices. Compared to pediatric and older adult patients, AYAs face a unique set of challenges.
Hesham Elhalawani +7 more
wiley +1 more source
Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin +17 more
wiley +1 more source
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
Drugs in Context, 2022 Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating KRAS mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is the most common KRAS ...
Biagio Ricciuti +10 more
doaj +1 more source
Organoids in pediatric cancer research
FEBS Letters, EarlyView.Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
Chronic obstructive pulmonary disease: a complex comorbidity of lung cancer [PDF]
, 2011 Chronic obstructive pulmonary disease (COPD) is a major burden throughout the world. It is associated with a significantly increased incidence of lung cancer and may influence treatment options and outcome.
Derek Grose MRCP, FRCR +3 more
core +1 more source